London
· Delayed Price · Currency is GBP · Price in GBXhVIVO Company Description
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom.
The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services.
It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD.
In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development.
Further, the company provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services.
The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Yamin Khan |
Contact Details
Address: 21 Plumbers Row London, E1 1EQ United Kingdom | |
| Phone | 44 20 7756 1300 |
| Website | hvivo.com |
Stock Details
| Ticker Symbol | HVO |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00B9275X97 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Yamin Khan | Chief Executive Officer |
| Stephen Pinkerton | Chief Financial Officer |